Immucell Corp (ICCC) Stock Price

ICCCStock

$10.75+72.00%52W

Market Cap$97.63M

P/E—

PEG Ratio—

Div yield—

Beta0.59

ICCC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)29.16%

Price vs S&P 500 (4W)7.45%

VGM Score60.79

P/CF (Annual)39.44x

Book Value / Share (Quarterly)$3.45

P/TBV (Annual)2.06x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.18%

Cash Flow / Share (Quarterly)$0.46

Price vs S&P 500 (YTD)62.87%

Gross Margin (TTM)40.32%

Net Profit Margin (TTM)2.57%

EPS (TTM)$0.08

10-Day Avg Trading Volume0.01M

EPS Excl Extra (TTM)$0.08

Revenue Growth (5Y)12.50%

EPS (Annual)$-0.12

ROI (Annual)-2.88%

Gross Margin (Annual)41.40%

Net Profit Margin (5Y Avg)-11.76%

Cash / Share (Quarterly)$0.98

P/E Basic Excl Extra (TTM)124.00x

Revenue Growth QoQ (YoY)11.50%

ROA (Last FY)-2.45%

Revenue Growth TTM (YoY)8.49%

EBITD / Share (TTM)$0.39

ROE (5Y Avg)-8.65%

Operating Margin (TTM)3.91%

Cash Flow / Share (Annual)$0.14

P/B Ratio3.11x

P/B Ratio (Quarterly)2.90x

Net Income / Employee (Annual)$-14,200

EV / Revenue (TTM)3.16x

Net Interest Coverage (TTM)-2.07x

ROA (TTM)1.76%

EPS Growth QoQ (YoY)259.17%

EV / EBITDA (TTM)27.16x

EPS Incl Extra (Annual)$-0.12

Current Ratio (Annual)4.26x

Quick Ratio (Quarterly)2.65x

3-Month Avg Trading Volume0.02M

52-Week Price Return72.00%

EV / Free Cash Flow (Annual)79.26x

P/E Incl Extra (TTM)124.00x

Revenue / Employee (TTM)$420,200

Tangible BV / Share (Quarterly)$2.99

P/S Ratio (Annual)3.53x

Asset Turnover (Annual)0.65x

52-Week High$12.10

Operating Margin (5Y Avg)-10.04%

EPS Excl Extra (Annual)$-0.12

CapEx CAGR (5Y)-21.02%

Tangible BV CAGR (5Y)-0.80%

26-Week Price Return39.07%

Quick Ratio (Annual)1.82x

13-Week Price Return-3.37%

Total Debt / Equity (Annual)0.34x

Current Ratio (Quarterly)4.75x

Enterprise Value$97.08M

Revenue / Share Growth (5Y)7.56%

Asset Turnover (TTM)0.69x

Book Value / Share Growth (5Y)-5.24%

Revenue / Employee (Annual)$378,700

Inventory Turnover (Annual)1.98x

Pretax Margin (Annual)-3.72%

Cash / Share (Annual)$0.42

3-Month Return Std Dev36.88%

Gross Margin (5Y Avg)35.95%

Net Income / Employee (TTM)$10,800

EBITDA CAGR (5Y)3.43%

EBITDA Interim CAGR (5Y)23.42%

ROE (Last FY)-3.84%

Net Interest Coverage (Annual)4.37x

EPS Basic Excl Extra (Annual)$-0.12

P/FCF (TTM)16.30x

Receivables Turnover (TTM)11.63x

EV / Free Cash Flow (TTM)23.03x

Total Debt / Equity (Quarterly)0.26x

EPS Incl Extra (TTM)$0.08

Receivables Turnover (Annual)7.69x

ROI (TTM)2.06%

P/S Ratio (TTM)3.18x

Pretax Margin (5Y Avg)-11.72%

Revenue / Share (Annual)$3.06

Tangible BV / Share (Annual)$2.99

Price vs S&P 500 (52W)56.47%

P/E Ratio (TTM)124.00x

EPS Growth TTM (YoY)-55.44%

Year-to-Date Return74.80%

5-Day Price Return11.98%

EPS Normalized (Annual)$-0.12

ROA (5Y Avg)-5.23%

Net Profit Margin (Annual)-3.76%

Month-to-Date Return9.69%

Cash Flow / Share (TTM)$-0.47

EBITD / Share (Annual)$0.23

Operating Margin (Annual)-2.14%

LT Debt / Equity (Annual)0.28x

P/CF (TTM)16.57x

ROI (5Y Avg)-6.10%

P/E Excl Extra (TTM)124.00x

LT Debt / Equity (Quarterly)0.22x

EPS Basic Excl Extra (TTM)$0.08

P/TBV (Quarterly)2.06x

P/B Ratio (Annual)2.06x

Inventory Turnover (TTM)2.11x

Pretax Margin (TTM)2.78%

Book Value / Share (Annual)$2.99

Price vs S&P 500 (13W)-6.06%

Beta0.59x

P/FCF (Annual)79.71x

Revenue / Share (TTM)$3.34

ROE (TTM)2.68%

52-Week Low$4.52

vGradeC

gGradeC

mGradeA

vgmGradeB

ICCC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2020	Feb 22, 2021	-$0.04	$0.03	+175.00%(+$0.07)
Q3 2020	Nov 12, 2020	-$0.08	-$0.04	+50.00%(+$0.04)
Q2 2020	Aug 12, 2020	-$0.10	-$0.11	-10.00%(-$0.01)
Q1 2020	May 13, 2020	—	-$0.02	—

ICCC Analyst Recommendations

Sep 2021

Oct 2021

Nov 2021

Dec 2021

4.14

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ICCCImmucell Corp	C	C	A	3.2x	8.5%	40.3%	—	$10.75
IDXXIdexx Laboratories Inc	D	B	B	9.7x	12.8%	62.5%	14.3%	$560.36
LNTHLantheus Holdings, Inc	C	B	B	4.2x	2.4%	61.0%	40.7%	$99.70
NEOGNeogen Corp	C	C	A	2.9x	-0.3%	47.4%	—	$11.81
CLDXCelldex Therapeutics, Inc	F	F	C	13683.0x	-97.3%	17.6%	—	$27.53
NTLAIntellia Therapeutics, Inc	D	D	C	26.9x	12.6%	—	—	$11.42
QDELQuidelOrtho Corporation Common Stock	C	C	C	0.3x	-2.5%	44.6%	—	$12.91
ACHVAchieve Life Sciences, Inc.	F	F	B	36.8x	-89.3%	—	—	$6.38
MYGNMyriad Genetics Inc	C	C	D	0.5x	-3.2%	68.8%	—	$3.98
TKNOAlpha Teknova, Inc. Common Stock	D	C	B	8.7x	12.3%	34.6%	—	$7.08
NNNNAnbio Biotechnology Class A Ordinary Shares	F	C	F	34.0x	-5.7%	89.0%	—	$3.13
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	59.0x	-60.8%	48.3%	—	$3.01
BMRABIOMERICA INC	B	D	B	1.9x	-16.2%	8.1%	—	$1.85
TRIBTrinity Biotech plc	B	D	C	0.1x	-16.6%	32.9%	—	$8.03
VNRXVolitionRx Limited	B	B	F	2.0x	86.3%	—	—	$0.18
CDIOCardio Diagnostics Holdings Inc. Common stock	—	D	C	345.9x	-25.9%	—	—	$1.69
QCLSQ/C Technologies, Inc. Common Stock	B	—	F	5.3x	—	24.7%	—	$0.54
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	F	156.9x	96.4%	62.0%	—	$1.45
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	F	—	—	—	—	$0.01

About Immucell Corp

ImmuCell Corp develops and commercializes health products for the dairy and beef cattle industries. The company operates two business segments: Scours (First Defense, a USDA-regulated product to prevent disease in newborn calves) and Mastitis (Re-Tain, an FDA-regulated treatment for subclinical mastitis in dairy cows). The Scours segment generates the majority of company revenue.